Pivotal Phase III Malaria Vaccine Trial Begins - Bill & Melinda Gates Foundation
In final testing of RTS,S, African research centers partner with GlaxoSmithKline Biologicals and PATH Malaria Vaccine Initiative for largest-ever malaria vaccine trial
LAMBARÉNÉ, Gabon -- The Phase III trial of the world’s most clinically-advanced malaria vaccine candidate began today in Gabon, marking the start of the largest malaria vaccine trial in history. Over the coming months, the trial of the RTS,S vaccine is expected to begin in 10 other sites in Burkina Faso, Ghana, Kenya, Malawi, Mozambique, and Tanzania, pending national reviews. Together, the sites will eventually enroll up to 16,000 children and infants.
To read the full press release, visit the PATH Malaria Vaccine Initiative web site.